A landmark $16M clinical trial led by Sylvester Comprehensive Cancer Center will assess AI's impact on radiologist performance in mammography screening.
Key Details
- 1PRISM is the first major randomized U.S. trial to study AI in breast cancer screening.
- 2Supported by a $16 million award from PCORI, the study spans hundreds of thousands of mammograms across six states.
- 3Seven academic medical centers, including UCLA and University of Miami, are participating.
- 4The trial uses Transpara by ScreenPoint Medical as the AI tool, integrated via Aidoc aiOS.
- 5Radiologists will remain in control of interpretations, with randomized assignment to AI-assisted or radiologist-only reads.
- 6Outcomes include cancer detection, recall rates, and perceptions of AI from both patients and clinicians.
Why It Matters
This large, multicenter trial could establish high-level evidence on the true value of AI assistance in real-world breast imaging, directly influencing clinical implementation, policy, and practice. Its patient-centered design and rigorous methodology will help clarify how—and for whom—AI can best improve breast cancer screening results.
Source
EurekAlert
Related News
•EurekAlert
UVA's $4M NIH Grant Backs AI to Optimize Cardiac MRI Therapies
UVA secures $4 million NIH funding to develop GenStrain, an AI model using MRI data to personalize cardiac pacing therapies.
•EurekAlert
Machine Learning Models Predict Cancer Risk with Routine Health Data
Researchers developed machine learning models using routinely collected health data to predict individual risk for 20 common cancers, outperforming traditional methods for several cancer types.
•EurekAlert
Duke Receives $25M to Lead National Trustworthy AI Hub for Dementia and Aging
Duke University has launched a $25 million national center to make AI for aging and dementia clinically robust and trustworthy.